A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Netherton Syndrome
In brief
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
Key facts
- Study ID
- NCT06539507
- Run by
- BioCryst Pharmaceuticals
- People needed
- 78
- Starts
- 2024-09-26
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-16
Who can join
Age: 12 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Yale Center for Clinical Investigation — New Haven, Connecticut, United States (enrolling)
- Maastricht Universitair Medisch Centrum (MUMC+) — Maastricht, Netherlands (enrolling)
- Erasmus Universitair Medisch Centrum (EMC) — Rotterdam, Netherlands (enrolling)
- Northwestern Dermatology CTU — Chicago, Illinois, United States (enrolling)
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States (enrolling)
- Westmead Hospital - Department of Dermatology — Sydney, New South Wales, Australia (enrolling)
- Therapeutics Clinical Research — San Diego, California, United States (enrolling)
- Veracity Clinical Research — Brisbane, Queensland, Australia (enrolling)
- Hôpital Saint-Louis — Paris, France (enrolling)
- Nucleus Network — Brisbane, Queensland, Australia
- Stanford University School of Medicine — Palo Alto, California, United States
- Universitätsklinikum Heidelberg — Heidelberg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.